List: The companies behind 38 new pharmaceutical substances in the EU

In 2025, the European Medicines Agency (EMA) recommended 104 medicines for approval. Of these, 38 contained a new active substance that had never before been au...

From Image to Results

3D multiplexing spatial omics workflows in neuroscience.

New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...

Positive outcome in phase III for Sanofi’s eczema treatment

The antibody amlitelimab shows positive Phase III data as a treatment for atopic dermatitis. France‑based Sanofi now plans to submit global regulatory applicati...

How the Nobel discovery is used in drug development

Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how t...

Gene therapy restored hearing in children with congenital deafness

Eleven out of twelve children with congenital deafness showed improvements in a study testing Regeneron’s gene therapy for hereditary hearing loss. The U.S. com...

Acne medication may be the solution when hair starts falling out

A treatment originally developed for acne has shown remarkable Phase III results in a completely different area: male-pattern hair loss.

Obesity dominates as future blockbusters are identified

Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.

PharmaRelations appoints new Chief Digital Officer and Executive VP Denmark

Press Release

“Access to capital increases when there’s an exit”

It remains a tough environment for biotech companies seeking financing – but there is good reason to hope for improvement ahead. That’s the view of Okee William...

Collaboration across the Øresund – Camurus enters Danish licensing agreement

Lund‑based Camurus has entered into a collaboration and licensing agreement with Danish company Gubra, which specializes in peptide‑based drug development.

Gothenburg-based Anyo Labs gains ground in the AI race

In a fifty-square-metre space in Gothenburg sits a company aiming to secure its place on one of the world's hottest technological stages: AI-driven drug develop...

The Beauty of Clinical Microscopy of Urine Sediment

Read about concrete observations using phase contrast and polarized light.

Experience innovations of the future

ZEISS QUALITY INNOVATIONS WORLDWIDE event in Oberkochen, Germany, January 20-21, 2026.

Shaping the Future of Metrology – Live in Your Region

Insights into our event series.

ZEISS EVO as the Key to Wire Technology in Modern Medicine

High-performance wires for stents.

Investor Network Backs Early-Stage Nordic Innovation

Life Science Invest is expanding into the Nordic region and has secured SEK 31 million to invest in early-stage research companies. The capital will be invested...

FDA’s new CSA guidance: transforming software validation for production and quality systems

FDA’s final guidance on Computer Software Assurance (CSA) for Production and Quality System Software marks a significant modernization of software validation practices.

Breakthrough devices: Key insights from MDCG 2025-9 guidance

The Medical Device Coordination Group (MDCG) has published guidance MDCG 2025-9 to streamline the pathway for breakthrough devices (BtX) under the EU Medical De...

Unlocking Predictive Insights for Drug Discovery and Development

3D tissue models webinar series.

Fourteen US-based top researchers recruited to Sweden

Last year, the government launched an initiative to attract leading researchers to Sweden, with a particular focus on academics based in the United States. As t...

Sneak Peek of ZEISS Metrology Expert Tips Season 2

The second season of the video series starts in January 2026, but you can discover more about the highlights of Season 2 now.

“There’s no magic wand” – The urgent need for new treatments

One in ten women with recurrent yeast infections develops a stubborn, hard-to-treat condition for which no effective therapies currently exist. At Danderyd Hosp...

Bioscience – Groundbreaking Research & Diagnostics: Gothenburg (2026)